Thu, January 23, 2025

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. ling of Dynatronics Corporation in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. ing of Iconix Brand Group, Inc. in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial selling of Telesis Bio, Inc. in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial selling of NORTH AMERICAN INDS in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. lling of Origin Materials, Inc. in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. ESG Global Impact Capital Inc. in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. cal Investment Holdings Limited in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. ng of Monumental Minerals Corp. in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. of Starbox Group Holdings Ltd. in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial .. of Tracker Financial Group Ltd in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial selling of Locafy Limited in recent trading

[ Thu, Jan 23rd 2025 ]: WOPRAI

As of Jan 23rd, 2025, there has been substantial selling of in recent trading

[ Thu, Jan 23rd 2025 ]: MSN

2 Growth Stocks to Buy in 2025 and Hold for a Decade

[ Thu, Jan 23rd 2025 ]: WOPRAI

138 Earnings Releases for Jan 23rd, 2025

[ Thu, Jan 23rd 2025 ]: cnbctv18

Ansid Capital recommends private banks, cautions on IT valuations
Wed, January 22, 2025

[ Wed, Jan 22nd 2025 ]: Moneyweb

To save or invest: Understanding the difference between stokvels and investing

[ Wed, Jan 22nd 2025 ]: Indiatimes

Stock Market Highlights : Nifty closes above 23,1 .. bullish momentum ahead. How to trade on Thursday

[ Wed, Jan 22nd 2025 ]: MSN

Want Almost $14,000 per Year in Dependable Passive Income? Invest $25,000 in These 4 Stocks

[ Wed, Jan 22nd 2025 ]: MSN

Want Decades of Passive Income? 4 Stocks to Buy Now and Hold Forever

[ Wed, Jan 22nd 2025 ]: Kiplinger

Stock Market Today: Earnings and AI Send Stocks to New Highs

[ Wed, Jan 22nd 2025 ]: MSN

Why Is Banco Santander, S.A. (SAN) Among the Best Large-Cap Value Stocks to Buy in 2025?

[ Wed, Jan 22nd 2025 ]: MSN

Why Is The Cigna Group (CI) Among the Best Large-Cap Value Stocks to Buy in 2025?

[ Wed, Jan 22nd 2025 ]: MSN

The Top Canadian Growth Stocks to Buy With $1,000

[ Wed, Jan 22nd 2025 ]: MSN

Netflix, Nvidia lead Wednesday's market cap stock movers

[ Wed, Jan 22nd 2025 ]: bnnbloomberg

S&P 500 Hits Record High as AI Powers Tech Rally: Markets Wrap

[ Wed, Jan 22nd 2025 ]: MSN

Why PBF Energy Inc. (PBF) Is One of the Worst Performing Energy Stocks in 2024?

[ Wed, Jan 22nd 2025 ]: MSN

Is Wynn Resorts (WYNN) the Best Sin Stock to Invest in 2025?

[ Wed, Jan 22nd 2025 ]: MSN

Is Churchill Downs Incorporated (CHDN) the Best Sin Stock to Invest in 2025?

[ Wed, Jan 22nd 2025 ]: AOL

Apple vs. Tesla: Which Tech Giant Will Be the Better Investment in 2025?

[ Wed, Jan 22nd 2025 ]: MSN

The 3 ETFs I'd Buy With $1,000 and Hold Forever

[ Wed, Jan 22nd 2025 ]: Kiplinger

Oracle Stock Surges on Trump's Stargate Project

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of CX at $5.64, after crossing above the $5.639 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of HDB at $61 .. 3, after crossing above the $61.012 Trigger Price

[ Wed, Jan 22nd 2025 ]: MSN

3 High-Yield Dividend ETFs to Buy to Generate Passive Income

[ Wed, Jan 22nd 2025 ]: Kiplinger

Is Netflix Stock Still a Buy After Earnings, Price Hikes?

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of USAU at $7 .. 25, after crossing above the $7.073 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of SWKH at $17, after crossing above the $16.895 Trigger Price

[ Wed, Jan 22nd 2025 ]: MSN

Truist sees AI boost for CRM and other tech stocks

[ Wed, Jan 22nd 2025 ]: bnnbloomberg

Trade War Threatens Canadian Banks Stocks' Rally After 27% Surge

[ Wed, Jan 22nd 2025 ]: Kiplinger

Procter & Gamble Stock Rises on Earnings Beat: What to Know

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of TRVG at $2 .. 75, after crossing above the $2.674 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of SQNS at $3 .. 76, after crossing above the $3.275 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of RGEN at $1 .. , after crossing above the $168.998 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of LMRMF at $ .. 95, after crossing above the $0.082 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of LIDRW at $ .. 77, after crossing above the $0.071 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of IVDAW at $ .. 47, after crossing above the $0.217 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of FSM at $4.36, after crossing above the $4.333 Trigger Price

[ Wed, Jan 22nd 2025 ]: WOPRAI

Short squeeze is starting in shares of DSKYF at $ .. 4, after crossing above the $29.765 Trigger Price

Exelixis's SWOT analysis: cabozantinib growth and zanzalintinib potential buoy stock

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product cabozantinib while advancing a promising pipeline led by zanzalintinib. According to InvestingPro data,
The article from MSN Money discusses Exelixis Inc., a biopharmaceutical company focused on oncology, detailing its SWOT analysis. Strengths include its flagship drug, Cabozantinib (marketed as Cabometyx and Cometriq), which has shown significant growth and is approved for treating various cancers, contributing to a robust revenue stream. Weaknesses are highlighted by the company's heavy reliance on Cabozantinib, with limited diversification in its product portfolio. Opportunities for Exelixis include the potential of zanzalintinib, a new drug candidate showing promise in clinical trials, which could expand its market if approved. Additionally, there's potential for expanding Cabozantinib's indications. Threats include competition from other cancer treatments, patent expirations, and the inherent risks of drug development like clinical trial failures. The article suggests that while Exelixis has a strong market position with Cabozantinib, its future growth and stock performance hinge significantly on the success of zanzalintinib and further development of its pipeline.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/exelixis-s-swot-analysis-cabozantinib-growth-and-zanzalintinib-potential-buoy-stock/ar-AA1xGLXa ]